Radical Prostatectomy Versus Radiotherapy in High-Risk Prostate Cancer

At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Christopher Wallis, MD, PhD, FRCSC, of the University of Toronto, spoke with Soumyajit Roy, MD, of Rush University Medical Center, on the treatment of localized prostate cancer.

They discuss Dr. Roy’s newly presented research on the CALGB-90203 (PUNCH) trial on radical prostatectomy with or without neoadjuvant docetaxel and ADT, and the NRG/RTOG-0521 trial comparing radiotherapy plus long-term ADT with or without adjuvant docetaxel.